Altimmune, Inc.ALTNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank21
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-67.84M
↓ 171% vs avg
Percentile
P21
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-25.04M
Historical baseline
PeriodValueYoY Change
TTM$-67.84M+15.0%
2024$-79.85M-5.3%
2023$-75.86M-21.0%
2022$-62.71M+30.7%
2021$-90.55M-161.3%
2020$-34.65M-260.8%
2019$-9.60M+7.7%
2018$-10.40M+48.9%
2017$-20.38M-110.1%
2016$201.48M-